Indaptus Therapeutics filed an SEC registration statement for the resale of 18.864 million common shares. This follows a private placement that raised approximately $12 million in gross proceeds. The company sold 20 million shares to non-U.S. accredited investors. These shares were priced at $0.60 per share.
Indaptus also paused patient enrollment in its Decoy20 clinical trial. The S-3 filing confirmed the suspension of the Decoy20 program. These actions signal a strategic re-evaluation and potential financial pressure for the biotechnology firm.